Viatronix V3D-Colon Utilized in 'Another' Land...( STONY BROOK N.Y. Oct. 4 /- Stony ...),Health

STONY BROOK, N.Y., Oct. 4 /PRNewswire/ -- Stony Brook based Viatronix Incorporated (http://www.viatronix.com), a leading innovator and developer of 3D imaging software announced today the publication of a new study in the New England Journal of Medicine, titled "CT Colonography versus Colonoscopy for the Detection of Advanced Neoplasia". The study utilized the Viatronix V3D- Colon platform exclusively.

The results published in the October 4th issue of the New England Journal of Medicine compared primary CTC screening in 3,120 adults with primary OC screening in 3,163 adults and found that primary CTC and OC for colon cancer screening provide similar detection rates for advanced neoplasia. Although the number of polypectomies and complications were considerably smaller in the CTC group. The study was conducted at the University of Wisconsin by Pickhardt et al., and concluded that the results support the use of CTC as a primary screening test before therapeutic OC. This once again proves that CTC screening with the Viatronix V3D-Colon is a safe, clinically effective, and cost-effective technique for colon cancer screening

About Viatronix

Viatronix is a leading innovator and developer of 2D/3D medical imaging and diagnostic software. Our software enables physicians to interactively view vital organs and anatomical structures within the human body from data acquired by standard medical imaging equipment in minimally or non-invasive methods. The 2D digital data acquired from imaging devices is automatically post processed using the company's proprietary software techniques and provides 3D diagnostic quality images for the physician. The company's first product, V3D-Colon for "virtual colonoscopy" allows physicians to interactively view the colon reconstructed from a CT scan, providing visualization of the entire colon wall which includes polyps and other lesions. The company's V3D-Explorer offe
'/>"/>